In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin: Anti-mycobacterial activity of KRM-1648

Arzneimittel-Forschung/Drug Research

Volumn 51, Issue 6, 2001, Pages 501-505

  Dhople, A M ^a  

^a Florida Institute of Technology   (United States)

Author keywords

Benzoxazinorifamycin; Buruli ulcer; CAS 129791 92 0; CAS 13292 46 1; KRM 1648, in vivo studies, mouse; Mycobacterium ulcerans; Rifampicin

Indexed keywords

RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE;

ADOLESCENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MOUSE; MYCOBACTERIUM ULCERANS; NONHUMAN;

EID: 0034950026     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300070     Document Type: Article

References (20)

1. Bull. Tuberculosis in developing countries: Burden, intervention and cost
2. Epidemiology of infection by notuberculosis mycobacteria
3. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
4. Epidemiology of diseases caused by nontuberculosis mycobacteria
5. A new mycobacterial infection in man
6. Buruli ulcer: A mycobacterial skin ulcer in a Uganda child
7. Investigation in the relationship of Mycobacterium ulcerans to Mycobacterium buruli
8. Prospective treatment for Mycobacterium ulcerans infection in rat and mice through combined therapy with rifampin and septran
9. Heat treatment of Mycobacterium ulcerans infections without surgical incision
10. The in vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae
11. In vivo activities of novel benzoxazinorifamycins against Mycobacterium leprae
12. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
13. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a mouse model
14. In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans
15. The experimental disease that follows the injection of human leprosy bacilli into footpads of mice
16. The use of rodent models in assessing antimicrobial activity against Mycobacterium leprae
17. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin